Efficacy and Safety of Yangxinshi versus Trimetazidine on Exercise Tolerance in Patients with Coronary Heart Disease after Percutaneous Coronary Intervention: Multicenter, Double-Blind Clinical Trial

Optimizing medication to improve exercise tolerance in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI) is limited. Yangxinshi tablets, an herbal-based oral medicine, relieve symptoms of angina might be that they can improve energy metabolism of the ischemic myocardium. We conducted a randomized trial to assess the efficacy and safety of Yangxinshi vs. trimetazidine in improving exercise tolerance in patients with CHD after PCI.